Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N., Celio Kussumoto, María Alejandra Álvarez et al.|Journal of Clinical Oncology|2023Cited by 317
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK.N. Chi, Eleni Efstathiou, Shahneen Sandhu et al.|Annals of Oncology|2023Cited by 195
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Douglas S. Barker et al.|Clinical Cancer Research|2011Cited by 168
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, Johann S. de Bono, David Olmos et al.|European Urology|2016Cited by 154
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC countsDavid Lorente, Johann S. de Bono, David Olmos et al.|Annals of Oncology|2018Cited by 97